Mark Cuban Upgrades TrumpRx to 'A-' — 'They're Doing A Good Job Actually' Says Denting Big Insurance Conglomerates Is A 'Win'

2 hours ago 2

Benzinga and Yahoo Finance LLC whitethorn gain committee oregon gross connected immoderate items done the links below.

Mark Cuban isn't grading for benignant points—he's grading for impact. The billionaire co-founder of Cost Plus Drugs revisited TrumpRx and made wide what matters most: if it pressures the close players, it's working.

From "B" To ‘A-' — Why The Grade Moved

Cuban said his archetypal instrumentality connected TrumpRx landed astatine a "B," noting pharmaceutical stocks hardly reacted aft the rollout, successful a station connected X successful September.

"I deliberation they're doing a bully occupation actually," helium told Healthcare Brew successful an interrogation published aboriginal this month. "Anytime that you dent those large security companies, those mega-conglomerates, that's a win."

Don't Miss:

The AI Marketing Platform Backed by Insiders from Google, Meta, and Amazon — Invest astatine $0.91/Share earlier the April 30 cutoff
Demand for Faster Diagnostics Is Surging — NASA- and NIH-Supported Space-Tested System Targets At-Home Lab-Quality Blood Testing

The difference, helium said, is traction. The level present lists 57 drugs, including IVF medications and GLP-1 treatments, expanding entree successful areas wherever prices person been a flashpoint. His concern with TrumpRx, announced successful October, was tied to that aforesaid idea—reach much patients, determination much product, little costs.

"Anything that saves patients wealth is simply a bully thing," helium told Healthcare Brew.

The Real Target Isn't Who It Looks Like

Cuban didn't walk the interrogation defending a platform—he spent it pointing astatine the operation down it.

"The top instrumentality the security companies ever played was putting the PBMs retired determination to instrumentality each the hits and pushing radical to disregard everything other that they're doing," helium told Healthcare Brew.

Pharmacy payment managers often instrumentality the blasted for precocious prices and entree issues. Cuban's constituent is that they're not the apical of the chain. The larger security companies that power them signifier pricing, coverage, and incentives successful ways that don't get the aforesaid scrutiny.

Trending: This Under-$1 Pre-IPO AI Company Is Still Open to Retail Investors — Learn More

The One Lever That Changes Everything

If helium could alteration 1 thing, Cuban didn't hesitate.

"Make it truthful PBMs didn't power formularies…because that's each their leverage," helium said successful the interview.

Formularies determine which drugs are covered and nether what terms. Take that power away, helium argues, and the pricing crippled changes quickly.

He pointed to authorities Medicaid systems arsenic impervious it tin work, wherever autarkic committees—not vertically integrated companies—decide what gets covered.

See Also: Deloitte's #1 Fastest-Growing Software Company Lets Users Earn Money Just by Scrolling — Investors Can Still Get In astatine $0.50/Share